查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970768

动物干细胞疗法市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031年

Animal Stem Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球动物干细胞治疗市场预计将从 2025 年的 2.4011 亿美元成长到 2031 年的 3.4389 亿美元，复合年增长率为 6.17%。

该领域专注于再生医学，利用自体或异体干细胞促进组织修復，特别适用于伴侣动物和马匹的骨关节炎和软组织损伤。推动该行业发展的主要因素是宠物人性化趋势的文化转变以及老龄化相关整形外科疾病发病率的上升。这些因素凸显了开发有效、非侵入性治疗方法以取代传统药物疗法的必要性。因此，人们对旨在显着改善老年动物生活品质的先进医疗干预措施的需求日益增长。

市场概览
预测期 2027-2031
市场规模：2025年 2.4011亿美元
市场规模：2031年 3.4389亿美元
复合年增长率：2026-2031年 6.17%
成长最快的细分市场 动物医院
最大的市场 北美洲

儘管成长潜力巨大，但该市场仍面临许多障碍，因为这些疗法的高昂费用限制了许多宠物饲主的接受度。除了经济限制外，不同司法管辖区缺乏统一的法规结构也是其广泛应用的主要障碍。根据美国宠物用品协会（APPA）的数据，2024年美国兽医医疗和产品总销售额将达398亿美元。虽然如此巨大的支出表明先进兽医解决方案拥有稳固的经济基础，但再生医学的高昂价格仍然是其普及应用的一大障碍。

市场驱动因素

慢性病和整形外科疾病的日益普遍是全球动物干细胞治疗市场的主要驱动力。随着伴侣动物寿命的延长，骨关节炎和软组织损伤等与老龄化相关的疾病发生率也在上升，因此迫切需要能够提供长期症状缓解而非仅仅缓解症状的再生疗法。 2025年6月《兽医时报》发表的一项关于早期骨关节炎诊断的临床评估显示，高达23.6%的幼犬出现该疾病的征兆，凸显了早期干预的紧迫性。慢性病发病率的上升趋势促使兽医将干细胞疗法作为缓解疾病方法纳入标准治疗方案中。

同时，伴侣动物日益普及以及宠物人性化趋势的增强，正显着加速市场成长。饲主越来越将宠物视为家庭成员，也更愿意投资先进的医疗手段来维护它们的健康。根据澳洲动物医学会2025年9月发布的报告，宠物拥有率预计将大幅成长，目前已有73%的家庭拥有宠物。这种情感纽带得益于经济保障的增强。北美宠物健康保险协会在2025年4月发布的报告显示，截至2024年底，美国宠物保险总保费将达到47亿美元，这使得扩大再生医学的覆盖范围在经济上成为可能。

市场挑战

再生医学手术费用飙升是全球动物干细胞治疗市场扩张的主要障碍。这些治疗方法涉及复杂的采集、处理和再植入通讯协定，需要专用设备和训练有素的兽医专业人员，因此成本极高。因此，目标客户群主要限于高所得宠物饲主，使得大多数市场参与者几乎无法获得这些先进的治疗。这种经济上的排他性阻碍了干细胞疗法成为多种整形外科疾病的标准疗法，使其仍然是小众的加值服务，而不是大众市场的解决方案。

近期兽医支出模式的变化进一步印证了这个经济障碍，显示消费者预算日益紧张。根据美国兽医协会（AVMA）统计，2024年美国宠物饲主在兽医方面的总支出较前一年下降了4%。支出下降凸显了消费者对医疗保健成本上涨的敏感性，并表明面临经济压力的饲主更有可能避免昂贵的非必要手术。由于干细胞疗法价格昂贵，这种普遍的支出减少趋势将直接阻碍市场扩张所需的普及率。

市场趋势

目前，市场正经历一场根本性的转变，从劳动密集的自体移植转向可扩展、即时取得的异体「现成」干细胞疗法。这一趋势将消除诸多物流障碍，使诊所能够储备通用供体细胞，从而缩短个别组织采集前置作业时间并降低治疗成本。目前，大量资金正被投入到推动大规模生产治疗方法的转型中。例如，DVM360在2025年7月报道称，Gallant Therapeutics已获得1,800万美元的B轮资金筹措，用于加速其即用型间质干细胞产品的商业化。

同时，将再生医学融入常规兽医诊疗通讯协定的趋势日益明显。这些治疗方法正从专科医院走向常规临床服务。集中处理和储存服务的日益普及，使得全科兽医能够越来越多地将再生医学应用于慢性疾病（例如骨关节炎）的治疗，而无需专门的医疗机构。这种主流化趋势体现在整个产业内不断上升的采用率。根据VetStem公司2025年4月发布的新闻稿，该公司已成功处理超过4万例干细胞疗法，这表明这些治疗方法正在标准兽医护理中发挥重要作用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球动物干细胞疗法市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（犬类干细胞疗法、马类干细胞疗法）
    • 依用途（兽医院、研究机构）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美动物干细胞疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲动物干细胞疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区动物干细胞疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲动物干细胞疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲动物干细胞疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球动物干细胞治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Ardent Animal Health LLC
  • Vet Stem Inc
  • Medrego Limited Liability Company（SIA）
  • Veterinary Regenerative Medicine
  • Celavie Biosciences LLC
  • Magellan Stem Cells Pty Ltd
  • Animal Cell Therapies, Inc.
  • Cell Therapy Sciences Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17596

The Global Animal Stem Cell Therapy Market is projected to expand from USD 240.11 Million in 2025 to USD 343.89 Million by 2031, reflecting a compound annual growth rate of 6.17%. This sector focuses on regenerative medical treatments that employ autologous or allogeneic stem cells to facilitate tissue repair, specifically targeting osteoarthritis and soft tissue injuries in companion animals and horses. The industry is primarily bolstered by the cultural shift toward pet humanization and the increasing incidence of age-related orthopedic ailments, which necessitate effective, non-invasive alternatives to conventional pharmaceutical management. Consequently, these drivers are fostering a rising demand for advanced healthcare interventions aimed at significantly improving the quality of life for aging animals.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 240.11 Million
Market Size 2031USD 343.89 Million
CAGR 2026-20316.17%
Fastest Growing SegmentVeterinary Hospitals
Largest MarketNorth America

Despite this growth potential, the market faces substantial obstacles due to the prohibitive costs associated with these procedures, which limit accessibility for many pet owners. Financial constraints, coupled with inconsistent regulatory frameworks across different jurisdictions, create significant barriers to mass adoption. Data from the American Pet Products Association indicates that veterinary care and product sales in the United States totaled $39.8 billion in 2024. While this substantial expenditure demonstrates a solid economic foundation for advanced veterinary solutions, the elevated price point of regenerative therapies remains a critical hurdle preventing widespread implementation.

Market Driver

The escalating prevalence of chronic and orthopedic veterinary diseases serves as the primary catalyst driving the global animal stem cell therapy market. As the lifespan of companion animals increases, so does the occurrence of age-related conditions such as osteoarthritis and soft tissue injuries, creating a critical need for regenerative treatments that provide long-term relief beyond simple palliative care. Clinical assessments referenced in a June 2025 Vet Times article on early osteoarthritis diagnosis reveal that up to 23.6% of young dogs now exhibit signs of the disease, underscoring the urgent demand for early-stage interventions. This growing burden of chronic illness compels veterinarians to integrate stem cell therapies as a standard, disease-modifying approach to care.

Concurrently, market growth is significantly amplified by the increasing adoption of companion animals and the trend of pet humanization. Owners increasingly view their pets as integral family members, demonstrating a higher propensity to invest in advanced medical procedures to ensure their well-being. A September 2025 report by Animal Medicines Australia notes that pet ownership rates have surged, with 73% of households now owning a pet. This emotional commitment is supported by strengthening financial safeguards; the North American Pet Health Insurance Association reported in April 2025 that total U.S. pet insurance premiums reached $4.7 billion by the end of 2024, providing the economic means to facilitate wider access to these regenerative therapies.

Market Challenge

The prohibitive cost of regenerative procedures acts as a major barrier restricting the scalability of the global animal stem cell therapy market. These therapies involve complex extraction, processing, and re-implantation protocols that require specialized equipment and highly trained veterinary personnel, leading to substantial treatment fees. Consequently, the addressable customer base is narrowed significantly to high-income pet owners, effectively rendering these advanced treatments inaccessible for the majority of the market. This economic exclusivity prevents stem cell therapy from becoming a standard of care for widespread orthopedic conditions, relegating it to a niche premium service rather than a mass-market solution.

This financial friction is further evidenced by recent shifts in veterinary consumption patterns, which indicate a tightening of consumer budgets. According to the American Veterinary Medical Association, overall veterinary spending by pet owners in the United States decreased by 4% in 2024 compared to the previous year. This contraction in expenditure highlights the sensitivity of clients to rising healthcare costs, suggesting that when faced with economic pressures, owners are likely to forgo expensive elective procedures. As stem cell treatments represent a significant financial outlay, this broader trend of reduced spending power directly dampens the adoption rates necessary for robust market expansion.

Market Trends

The market is undergoing a fundamental transition toward allogeneic "off-the-shelf" stem cell therapies, moving away from labor-intensive autologous procedures to scalable, immediately available solutions. This trend addresses critical logistical barriers by enabling clinics to stock universal donor cells, thereby reducing the lead times and procedural costs associated with individual tissue harvesting. Significant capital is currently supporting this pivot toward mass-producible therapeutics; for instance, DVM360 reported in July 2025 that Gallant Therapeutics secured $18 million in Series B financing specifically to accelerate the commercialization of its off-the-shelf uterine-derived mesenchymal stem cell products.

Simultaneously, the integration of regenerative medicine into general veterinary practice protocols is expanding, as these therapies graduate from niche specialty hospitals to routine clinical offerings. Enhanced access to centralized processing and banking services has allowed general practitioners to increasingly incorporate regenerative treatments for chronic conditions like osteoarthritis without requiring specialized onsite laboratory infrastructure. This mainstream adoption is quantified by rising usage rates across the sector; according to a broad press release by VetStem, Inc. in April 2025, the company has successfully processed over 40,000 stem cell treatments, demonstrating the established role of these interventions in standard veterinary care.

Key Market Players

  • Ardent Animal Health LLC
  • Vet Stem Inc
  • Medrego Limited Liability Company (SIA)
  • Veterinary Regenerative Medicine
  • Celavie Biosciences LLC
  • Magellan Stem Cells Pty Ltd
  • Animal Cell Therapies, Inc.
  • Cell Therapy Sciences Ltd

Report Scope

In this report, the Global Animal Stem Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Stem Cell Therapy Market, By Type

  • Dogs Stem Cell Therapy
  • Horses Stem Cell Therapy

Animal Stem Cell Therapy Market, By Application

  • Veterinary Hospitals
  • Research Organizations

Animal Stem Cell Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Stem Cell Therapy Market.

Available Customizations:

Global Animal Stem Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Stem Cell Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Dogs Stem Cell Therapy, Horses Stem Cell Therapy)
    • 5.2.2. By Application (Veterinary Hospitals, Research Organizations)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Animal Stem Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Animal Stem Cell Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Animal Stem Cell Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Animal Stem Cell Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Animal Stem Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Animal Stem Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Animal Stem Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Animal Stem Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Animal Stem Cell Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Animal Stem Cell Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Animal Stem Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Animal Stem Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Animal Stem Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Animal Stem Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Animal Stem Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Animal Stem Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Animal Stem Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Animal Stem Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Animal Stem Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Animal Stem Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Animal Stem Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Animal Stem Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Animal Stem Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Animal Stem Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Animal Stem Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ardent Animal Health LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Vet Stem Inc
  • 15.3. Medrego Limited Liability Company (SIA)
  • 15.4. Veterinary Regenerative Medicine
  • 15.5. Celavie Biosciences LLC
  • 15.6. Magellan Stem Cells Pty Ltd
  • 15.7. Animal Cell Therapies, Inc.
  • 15.8. Cell Therapy Sciences Ltd

16. Strategic Recommendations

17. About Us & Disclaimer